Acsh.org1d
Chaos in the Courts: Updates, Insights, and How to Store Valsartan Meds
The theory against these was launched from the Zantac claims, which are still clogging court calendars. In early October, ...
STAT4d
Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more
We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...
Federal law could prevent your 23andMe data deletion, but you should still try
Requesting deletion closes your account permanently and prevents your data from being used in further research (existing ...
FierceBiotech2d
GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
GSK’s Withdrawn Blood Cancer Drug Reduced Risk of Death in Trial
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
FiercePharma6d
GSK calls it quits on trade group BIO for 2025, following exits by Takeda, UCB and more
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
GlaxoSmithKline (GSK) was downgraded to a Hold Rating at Jefferies
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
GlaxoSmithKline (GSK) Receives a Buy from Bernstein
Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
BioPharma Dive2d
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...